Insider Monkey
Novo Nordisk (NVO) Faces Pricing Pressure While Defending Wegovy Franchise and Advancing Oral GLP-1s
📉
AI Sentiment
Negative
3/10
- Home
- HIMS
as of 02-09-2026 3:59pm EST
$19.33
$3.72
-16.14%
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 6.9B | IPO Year: | N/A |
| Target Price: | $40.55 | AVG Volume (30 days): | 22.0M |
| Analyst Decision: | Hold | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.54 | EPS Growth: | 20.76 |
| 52 Week Low/High: | $21.12 - $72.98 | Next Earning Date: | 02-23-2026 |
| Revenue: | $2,210,958,000 | Revenue Growth: | 78.02% |
| Revenue Growth (this year): | 62.27% | Revenue Growth (next year): | 17.90% |
| P/E Ratio: | 42.88 | Index: | N/A |
| Free Cash Flow: | 133.9M | FCF Growth: | -16.79% |
AI-Powered HIMS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.31%
75.31%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Hims & Hers Health Inc. (HIMS)
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Feb 3, 2026
Avg Cost/Share
$26.44
Shares
5,262
Total Value
$139,107.81
Owned After
91,617
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Jan 20, 2026
Avg Cost/Share
$30.34
Shares
9,067
Total Value
$275,113.63
Owned After
91,617
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Jan 5, 2026
Avg Cost/Share
$33.79
Shares
9,070
Total Value
$306,452.63
Owned After
91,617
SEC Form 4
Okupe Oluyemi
Sell
Chief Financial Officer
HIMS Dec 22, 2025
Avg Cost/Share
$35.72
Shares
23,090
Total Value
$824,710.15
Owned After
91,617
SEC Form 4
Carroll Patrick Harrison
Sell
Chief Medical Officer
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
10,021
Total Value
$367,870.91
Owned After
169,940
SEC Form 4
Becklund Irene
Sell
PAO
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
8,411
Total Value
$308,767.81
Owned After
2,126
SEC Form 4
Chi Michael
Sell
Chief Operating Officer
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
13,750
Total Value
$504,762.50
Owned After
305,161
SEC Form 4
Autor Deborah M.
Sell
Chief Policy Officer
HIMS Dec 17, 2025
Avg Cost/Share
$36.71
Shares
7,054
Total Value
$258,952.34
Owned After
6,175
SEC Form 4
Perez Garcia Andrea G
Sell
Director
HIMS Dec 9, 2025
Avg Cost/Share
$39.17
Shares
2,500
Total Value
$97,925.00
Owned After
80,166
SEC Form 4
Boughton Soleil
Sell
Chief Legal Officer
HIMS Nov 24, 2025
Avg Cost/Share
$35.22
Shares
2,631
Total Value
$92,663.82
Owned After
153,225
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | HIMS | Chief Financial Officer | Feb 3, 2026 | Sell | $26.44 | 5,262 | $139,107.81 | 91,617 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Jan 20, 2026 | Sell | $30.34 | 9,067 | $275,113.63 | 91,617 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Jan 5, 2026 | Sell | $33.79 | 9,070 | $306,452.63 | 91,617 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Dec 22, 2025 | Sell | $35.72 | 23,090 | $824,710.15 | 91,617 | |
| Carroll Patrick Harrison | HIMS | Chief Medical Officer | Dec 17, 2025 | Sell | $36.71 | 10,021 | $367,870.91 | 169,940 | |
| Becklund Irene | HIMS | PAO | Dec 17, 2025 | Sell | $36.71 | 8,411 | $308,767.81 | 2,126 | |
| Chi Michael | HIMS | Chief Operating Officer | Dec 17, 2025 | Sell | $36.71 | 13,750 | $504,762.50 | 305,161 | |
| Autor Deborah M. | HIMS | Chief Policy Officer | Dec 17, 2025 | Sell | $36.71 | 7,054 | $258,952.34 | 6,175 | |
| Perez Garcia Andrea G | HIMS | Director | Dec 9, 2025 | Sell | $39.17 | 2,500 | $97,925.00 | 80,166 | |
| Boughton Soleil | HIMS | Chief Legal Officer | Nov 24, 2025 | Sell | $35.22 | 2,631 | $92,663.82 | 153,225 |
Latest Hims & Hers Health Inc. News
HIMS Breaking Stock News: Dive into HIMS Ticker-Specific Updates for Smart Investing
Simply Wall St.
Novo Nordisk Tests Obesity Drug Moat As Regulators Target GLP 1 Copycats
➖
AI Sentiment
Neutral
5/10
Associated Press Finance
Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill
📉
AI Sentiment
Negative
2/10
Investor's Business Daily
Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown
📉
AI Sentiment
Negative
2/10
Barrons.com
Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny
📉
AI Sentiment
Negative
3/10
Financial Times
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
📉
AI Sentiment
Negative
3/10
BioPharma Dive
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
📉
AI Sentiment
Negative
3/10
Benzinga
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action
📉
AI Sentiment
Negative
3/10
Compare HIMS vs Leading Stocks
See how HIMS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HIMS Hims & Hers Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.